|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 440.87 USD | -1.68% |
|
-3.20% | +9.48% |
| Capitalization | 113B 98.28B 92.57B 84.2B 155B 9,799B 176B 1,093B 419B 4,487B 425B 416B 16,535B | P/E ratio 2025 * |
29.3x | P/E ratio 2026 * | 25x |
|---|---|---|---|---|---|
| Enterprise value | 104B 90.37B 85.12B 77.42B 143B 9,010B 161B 1,005B 385B 4,126B 391B 382B 15,204B | EV / Sales 2025 * |
8.74x | EV / Sales 2026 * | 7.39x |
| Free-Float |
99.04% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | -1.68% | ||
| 1 week | -3.20% | ||
| Current month | -0.27% | ||
| 1 month | -1.41% | ||
| 3 months | -13.59% | ||
| 6 months | +10.97% | ||
| Current year | +9.48% |
| 1 week | 436.8 |  | 457.23 |
| 1 month | 427.43 | | 460.33 |
| Current year | 397.24 | | 519.68 |
| 1 year | 377.85 | | 519.88 |
| 3 years | 266.44 | | 519.88 |
| 5 years | 176.36 | | 519.88 |
| 10 years | 71.46 | | 519.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 2020-03-31 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 2019-04-09 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 65 | 1997-12-31 |
Jeffrey Leiden
CHM | Chairman | 69 | 2012-04-30 |
Sangeeta Bhatia
BRD | Director/Board Member | 56 | 2015-06-17 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.68% | -3.20% | -6.47% | +67.57% | 113B | ||
| -2.84% | -6.91% | -13.91% | +162.20% | 685B | ||
| -0.62% | -4.65% | +1.36% | -11.61% | 360B | ||
| -0.10% | -3.02% | +7.65% | +34.00% | 327B | ||
| -2.58% | -7.83% | -52.12% | +25.00% | 326B | ||
| -0.27% | -3.86% | +3.72% | -14.84% | 255B | ||
| -0.34% | -2.34% | +0.59% | +19.15% | 228B | ||
| -1.52% | -5.41% | -16.18% | +3.36% | 217B | ||
| -0.29% | -3.24% | -39.03% | -6.57% | 199B | ||
| -0.10% | -2.00% | -6.63% | +23.27% | 156B | ||
| Average | -1.03% | -4.07% | -12.10% | +30.15% | 286.52B | |
| Weighted average by Cap. | -1.32% | -4.65% | -12.38% | +47.97% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 11.91B 10.34B 9.74B 8.86B 16.35B 1,031B 18.46B 115B 44.05B 472B 44.67B 43.72B 1,739B | 13.22B 11.48B 10.81B 9.84B 18.16B 1,145B 20.5B 128B 48.93B 524B 49.62B 48.56B 1,932B |
| Net income | 3.89B 3.38B 3.18B 2.9B 5.35B 337B 6.04B 37.58B 14.41B 154B 14.61B 14.3B 569B | 4.57B 3.97B 3.74B 3.4B 6.28B 396B 7.09B 44.15B 16.93B 181B 17.17B 16.8B 668B |
| Net Debt | -9.12B -7.91B -7.45B -6.78B -12.52B -789B -14.13B -87.97B -33.73B -361B -34.2B -33.47B -1,331B | -15.49B -13.45B -12.67B -11.52B -21.27B -1,341B -24.01B -149B -57.31B -614B -58.12B -56.87B -2,262B |
More financial data
* Estimated data
Employees
6,100
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-20 | 440.87 $ | -1.68% | 2,167,405 |
| 25-06-18 | 448.40 $ | +1.45% | 1,380,456 |
| 25-06-17 | 441.99 $ | -1.98% | 1,363,520 |
| 25-06-16 | 450.91 $ | -1.00% | 1,030,124 |
| 25-06-13 | 455.45 $ | -1.00% | 1,021,563 |
Delayed Quote Nasdaq, June 20, 2025 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
440.87USD
Average target price
499.87USD
Spread / Average Target
+13.38%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition